Rosetta Genomics Receives Two Key U.S. Patent Allowances

           Rosetta Genomics Receives Two Key U.S. Patent Allowances

Protects Composition of Matter and Sequencing Variants Core to its
microRNA-based Molecular Diagnostics

PR Newswire

PHILADELPHIA and REHOVOT, Israel, Feb. 14, 2013

PHILADELPHIA and REHOVOT, Israel, Feb. 14, 2013 /PRNewswire/ --Rosetta
Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of
microRNA-based molecular diagnostics, today announced that the Company has
received two notices of allowance from the U.S. Patent and Trademark Office
("USPTO") for Patent Applications 12/661,041 and 12/850,091.

The allowed claims of 12/661,041, entitled "microRNAs and Uses Thereof," cover
the composition of matter for miR-29c*, as well as sequence variants (90%
identical thereto), a vector and a probe comprising the same. miR-29c* is a
core element in the Company's lead commercial product, miRview^® mets^2
diagnostic assay for the identification of the tumor of origin in Cancer of
Unknown and Uncertain Primary ("CUP"). 

The allowed claims of 12/850,091, entitled "Viral and Viral Associated MiRNAs
and Uses Thereof," cover the composition of matter for herpes simplex virus 1
miR-H3, miR-H4 and miR-H5, as well as sequence variants (80% identical
thereto), a vector and a complementary sequence comprising the same.

"The allowance of these key U.S. patents is central to our growing patent
portfolio as they protect core composition of matter and sequencing variants
for our lead marketed product," stated Kenneth A. Berlin, President and CEO of
Rosetta Genomics. "In addition, obtaining patent coverage for additional viral
microRNAs, expands our leadership in microRNA and offers us the potential to
license, partner or otherwise derive value from this powerful technology in
viral diseases. These allowances continue to fortify our dominant patent
position in microRNA technology, while creating additional barriers to entry
for any would-be competitors."

Rosetta Genomics maintains a robust intellectual property strategy to protect
its leadership position in microRNA technology. Rosetta's portfolio includes
29 issued patents, including 25 in the U.S. In addition, Rosetta has 42
patent applications, including 21 in the U.S.

About miRview^® Products
miRview^® are a series of microRNA-based diagnostic products offered by
Rosetta Genomics. miRview^® mets² accurately identifies the primary tumor type
in primary and metastatic cancer including CUP. miRview^®meso diagnoses
mesothelioma, a cancer connected to asbestos exposure. miRview^® lung
accurately identifies the four main subtypes of lung cancer using small
amounts of tumor cells. miRview^® kidney accurately classifies the four most
common kidney tumors: clear cell renal cell carcinoma (RCC), papillary RCC,
chromophobe RCC and oncocytoma. miRview^® tests are designed to provide
objective diagnostic data; it is the treating physician's responsibility to
diagnose and administer the appropriate treatment. In the U.S. alone, Rosetta
Genomics estimates that 200,000 patients a year may benefit from the miRview^®
mets² test, 60,000 from miRview^®meso, 54,000 from miRview^® kidney and
226,000 patients from miRview^® lung. The Company's assays are offered
directly by Rosetta Genomics in the U.S., and through distributors around the
world. For more information, please visit www.mirviewdx.com. Parties
interested in ordering the test can contact Rosetta Genomics at (215) 382-9000
ext. 309.

About Rosetta Genomics
Rosetta develops and commercializes a full range of microRNA-based molecular
diagnostics. Founded in 2000 Rosetta's integrative research platform
combining bioinformatics and state-of-the-art laboratory processes has led to
the discovery of hundreds of biologically validated novel human microRNAs.
Building on its strong patent position and proprietary platform technologies,
Rosetta is working on the application of these technologies in the development
and commercialization of a full range of microRNA-based diagnostic tools.
Rosetta's miRview® product line is commercially available through its
Philadelphia-based CAP-accredited, CLIA-certified lab. Frost & Sullivan
recognized Rosetta Genomics with the 2012 North American Next Generation
Diagnostics Entrepreneurial Company of the Year Award.

Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's future expectations,
plans and prospects, including without limitation, statements relating
toRosetta'sstrategic plan,the market acceptance of Rosetta's
miRview^®assays,particularly miRview^®mets^2,Rosetta's capitalization of
its microRNA platform, Rosetta's patent positionand Rosetta's development of
personalized medicine productsconstitute forward-looking statements for the
purposes of the safe harbor provisions under The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those indicated
by these forward-looking statements as a result of various important factors,
including those risks more fully discussed in the "Risk Factors" section of
Rosetta's Annual Report on Form 20-F for the year ended December 31, 2011as
filed with the SEC. In addition, any forward-looking statements represent
Rosetta's views only as of the date of this release and should not be relied
upon as representing its views as of any subsequent date. Rosetta does not
assume any obligation to update any forward-looking statements unless required
by law.

Company Contact:              Investor Contacts:
Rosetta Genomics              LHA
Ken Berlin, President & CEO   Anne Marie Fields
(215) 382-9000, ext. 326     (212) 838-3777
investors@rosettagenomics.com afields@lhai.com
                              or
                              Bruce Voss
                              (310) 691-7100
                              bvoss@lhai.com

SOURCE Rosetta Genomics Ltd.